• GLI2–PRDX1 Axis in Bladder Cancer Ferroptosis

  2026-09-30

  A 2026 Apoptosis study identifies GLI2 as a transcriptional driver of ferroptosis resistance in bladder cancer through PRDX1 upregulation. Its integrated GEO, RNA-sequencing, ChIP, perturbation, rescue, and drug-sensitization experiments position the GLI2–PRDX1 axis as a mechanistic link between tumor progression and cisplatin response.

• NF 449 as a Selective P2X1 Antagonist

  2026-09-29

  Rettinger and colleagues used recombinant rat P2X receptors in Xenopus oocytes to show that the suramin analogue NF 449 is an exceptionally potent antagonist of receptors containing the P2X1 subunit. The study provides a rigorous pharmacological basis for using NF 449 to separate P2X1 signaling from responses mediated by other ATP-gated channels, while also defining important limits for translation to platelet biology.

• Coronavirus Macrodomains and PARP-Mediated Antiviral Defense

  2026-09-29

  Grunewald and colleagues showed that coronavirus macrodomains counter host PARP-dependent ADP-ribosylation, thereby protecting viral replication and shaping interferon production. By combining pharmacologic inhibition, PARP12 and PARP14 knockdown, comparative virus genetics, and infection models, the study defined a mechanistic link between viral macrodomain activity and innate immune control.

• Angiotensin III Workflows for RAAS Research

  2026-09-28

  Build controlled RAAS, receptor-signaling, and exploratory spike-binding assays with Angiotensin III (human, mouse). This workflow emphasizes fresh-solution handling, concentration design, orthogonal readouts, and clear boundaries between established endocrine biology and emerging viral-receptor observations.

• CTOP for μ-Opioid Receptor Research

  2026-09-28

  Use CTOP to test whether μ-opioid receptor activation contributes to opioid-driven signaling and mechanical hypersensitivity. A practical workflow links receptor-level controls to the brain–spinal circuit findings of a 2024 mouse study, while keeping CTOP’s role distinct from cell-type-specific methods.

• TG003 Workflow for Clk-Linked Splicing Research

  2026-09-27

  TG003 offers a reversible way to probe Clk-dependent phosphorylation and alternative splice-site choice, with a workflow designed to separate splicing effects from broader kinase and cell-state changes. The article also explains how to use the ovarian-cancer CLK2 findings to shape testable experiments—without implying that TG003 was validated in that study.

• Genistein in Mechanostress Autophagy Research

  2026-09-26

  Use Genistein to test whether growth-factor kinase signaling contributes to stress responses—while keeping cytoskeletal force sensing and drug effects experimentally distinct. This workflow pairs dose-aware cell assays with mechanical-stress controls to help interpret autophagy, proliferation, and cell-death readouts.

• E. coli Uracil-DNA Glycosylase (UDG) Workflow

  2026-09-25

  E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, excises uracil from single- and double-stranded DNA and can be used to reduce carryover from uracil-containing PCR products. It is not active on RNA or oligonucleotides shorter than six bases, and is intended for research workflows rather than diagnostic or medical use.

• Protease Inhibitor Cocktail for CRC Signaling Studies

  2026-09-25

  Protect signaling proteins during colorectal cancer lysate preparation with an EDTA-free, DMSO-based inhibitor format that can suit workflows requiring divalent cations. This practical guide connects careful sample handling to the PI3K/AKT/mTOR findings in a recent tetrahydrocurcumin-derivative study—without implying the researchers used this product.

• Milk EV Uptake in Porcine Intestinal Stem Cell Models

  2026-09-24

  This study compares three porcine intestinal stem cell–based models to show how epithelial polarity and intestinal region shape uptake and responses to milk-derived extracellular vesicles. Its model-validation and inhibition experiments offer a more physiologically relevant framework for investigating vesicle access, internalization, and epithelial effects than cell-line assays alone.

• DMG-PEG2000-NH2: Linker Facts & Workflow

  2026-09-24

  DMG-PEG2000-NH2 is an NH2-PEG derivative with a primary amine intended for coupling to compatible carboxyl-containing molecules. The product information reports its molecular weight, solvent-specific solubility, purity, and storage condition; these specifications describe the material, not proven delivery performance.

• Endothelial SGK1 Mediates Salt-Related Vascular Stiffening

  2026-09-23

  Zhang et al. combine genetic mouse models with human aortic endothelial-cell experiments to identify endothelial SGK1 as a mediator of salt- and mineralocorticoid-associated vascular stiffening. Their findings connect SGK1 activity with endothelial actin polymerization and support further mechanistic work on salt-sensitive vascular dysfunction, while leaving clinical efficacy and the precise downstream pathway unresolved.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-09-23

  A 2025 study found that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to AXL, with shorter and N-terminally truncated peptides showing particularly strong effects. The work links renin–angiotensin biology to viral receptor engagement while emphasizing that the evidence currently comes from antibody-based binding assays rather than infection or clinical studies.

• Cabazitaxel (XRP6258) Workflow Guide

  2026-09-22

  Cabazitaxel (XRP6258, SKU B2157) supports cell-based studies of microtubule dynamics disruption, antiproliferative responses, and taxane-resistant cancer models. It is water-insoluble, so use validated DMSO- or ethanol-based preparation and prompt solution use rather than direct aqueous preparation or long-term solution storage.

• HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L)

  2026-09-22

  Learn how HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody, SKU K1214, can strengthen orthogonal fluorescence readouts in viability, proliferation, cytotoxicity, and hypoxia studies. This scenario-based guide covers compatibility, protocol control, interpretation, and practical vendor-selection criteria.

673 records 1/45 page Next 12345 下5页 Last page